chartexchange

Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

GlobeNewswire Inc. | Nov 12, 2026 4:15 PM EST

— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement —

Read original article